Genmab — Oktober 2016
-
Data fra fase III studiet POLLUX med daratumumab publiceret i New England Journal of Medicine
-
Det er rigtig godt nyt. Som Novod skrev i hans seneste breafing - 'This should, according to the expert, lead to rapid inclusion of Darzalex in the US NCCN guidelines with a category 1 evidence (strongest rating) for second-line myeloma' (om effekten af en artikel i NEMJ eller Lancet).
-
-
God morgen og tak for info og links.

-
Det link som JKY har lagt kl. 6,55 giver en forholdsvis let forståelig beskrivelse af Darzalex-casen. Kan varmt anbefales at læse.
-
Interessant kommentar fra en anden patient til det indlæg jkj linker til: You are my hero, Maureen, and tougher than I! I'm scheduled for my 50th (3 years) high-dose Darzalex infusion on October 11, 2016. My M-spike has been 0.0 for almost 3 years, and I hope yours will become likewise!
-
Dvs Novod tror på en godkendelse i år.
-
-
Jeg har siden august haft en tyrkertro på november.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind